Insiders | Shares | % | Avg Price | Total $ | |
---|---|---|---|---|---|
Buys | 0 | ||||
Sells | 1 | -7.52K | 100% | $6.94 | -$52.2K |
Net | -1 | -7.52K | -100% | -$52.2K |
Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Longitude Capital Partners III, LLC | 10%+ Owner | $14.9M | Apr 19, 2022 | ||
Pivotal bioVenture Partners Fund I, L.P. | Director | $5.61M | Aug 1, 2023 | ||
Robert Hopfner | Director | $5.61M | Jun 18, 2024 | ||
Douglas A. Treco | CEO, Director | $393K | -$52.2K | -11.7% | Apr 1, 2024 |
Henric Bjarke | Svp, Coo | $376K | Dec 15, 2022 | ||
Sanjay Subramanian | Svp, Cfo | $109K | Mar 13, 2024 | ||
Matthew Winton | Coo | $10.6K | Mar 28, 2024 | ||
Stephen J. DiPalma | Interim CFO | May 17, 2021 | |||
Lynne Sullivan | Director | Jun 18, 2024 | |||
Edward T. Mathers | Director | Jun 18, 2024 | |||
Reinaldo M. Diaz | Director | Jun 18, 2024 | |||
Martin Edwards | Director | Jun 18, 2024 | |||
Axel Bolte | Director | Jun 18, 2024 | |||
Inozyme Pharma, Inc. | Director | Jun 23, 2021 | |||
Sarah Bhagat | Director | Jun 18, 2024 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|